Corcept Therapeutics Incorporated CORT
Composite 51/100; the shares have moved about 65% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 16/100 — a strong mark against it.
Balance-sheet strength ranks 95/100 — a strong point in its favour. Momentum ranks 78/100 — a strong point in its favour.
Valuation ranks 16/100 — a strong mark against it. Growth ranks 30/100 — a moderate mark against it. Quality ranks 40/100 — a slight mark against it.
What the company does Corcept Therapeutics (CORT) develops selective cortisol modulators for severe endocrine, oncologic, metabolic, and neurologic disorders. Its lead drug, Korlym, treats hyperglycemia secondary to hypercortisolism in Cushing’s syndrome patients. The pipeline includes relacorilant (Phase 3 for Cushing’s), miricorilant (Phase 1b for MASH), and programs for ALS.
Key financials Revenue grew 4.9% YoY, but net margins remain thin at 6.2% despite gross margins of 98.3%. ROE is 7.2%, ROA -0.6%, and ROCE 1.8%. Forward P/E is 117.65 (PEG 0.89), with EV/EBITDA at 99.13 and P/B of 16.05.
Stock health Momentum is strong: +153.96% (3m), +158.06% (6m), +73.49% (12m), though down -3.18% from its 52w high. RSI(14) is 76.60, indicating overbought conditions. Strength pillar score is 76.1, while quality scores 35.0.
Price vs fair value CORT trades at a **discount of 37.70%** to our fair-value estimate of 162.88 and a **PREMIUM of 0.48%** to the analyst 12-month target of 117.75. - Q2 2026 earnings and revenue beat estimates, with 2026 outlook raised (Zacks, 2026-07-30) - Stock hit a 52-week high after Q2 results (Stocktwits, 2026-07-30) - Earnings call highlighted record revenue (GuruFocus.com, 2026-07-30) - Stock surged 17.4% on bullish Q2 report (StockStory, 2026-07-29)
Looking forward Relacorilant’s Phase 3 data and miricorilant’s MASH trial results are key catalysts. Analysts cite pipeline progress as supporting the premium to target. Execution risks remain tied to clinical outcomes and commercialization.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.